title: Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.
abstract: We previously demonstrated that amplified in breast cancer 1 (AIB1) and eukaryotic initiation factor 2 (EIF5A2) overexpression was an independent predictor of poor clinical outcomes for patients with bladder cancer (BCa). In this study, we evaluated the usefulness of AIB1 and EIF5A2 alone and in combination with nuclear matrix protein 22 (NMP22) as noninvasive diagnostic tests for BCa. Using urine samples from 135 patients (training set, controls [n = 50] and BCa [n = 85]), we detected the AIB1, EIF5A2, and NMP22 concentrations using enzyme-linked immunosorbent assay. We applied multivariate logistic regression analysis to build a model based on the three biomarkers for BCa diagnosis. The diagnostic accuracy of the three biomarkers and the model were assessed and compared by the area under the curve (AUC) of the receiver operating characteristic. We validated the diagnostic accuracy of these biomarkers and the model in an independent validation cohort of 210 patients. In the training set, urinary concentrations of AIB1, EIF5A2, and NMP22 were significantly elevated in BCa. The AUCs of AIB1, EIF5A2, NMP22, and the model were 0.846, 0.761, 0.794, and 0.919, respectively. The model had the highest diagnostic accuracy when compared with AIB1, EIF5A2, or NMP22 (p < 0.05 for all). The model had 92% sensitivity and 92% specificity. We obtained similar results in the independent validation cohort. AIB1 and EIF5A2 show promise for the noninvasive detection of BCa. The model based on AIB1, EIF5A2, and NMP22 outperformed each of the three individual biomarkers for detecting BCa.
authors.affiliation: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.|Department of Urology, Hainan Provincal Nongken General Hospital, Haikou, Hainan, China.
authors.forename: Bang-Fen
authors.initials: BF
authors.lastname: Zhou
authors.affiliation: Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Jin-Huan
authors.initials: JH
authors.lastname: Wei
authors.affiliation: Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Zhen-Hua
authors.initials: ZH
authors.lastname: Chen
authors.affiliation: Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Pei
authors.initials: P
authors.lastname: Dong
authors.affiliation: Department of Pathology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Ying-Rong
authors.initials: YR
authors.lastname: Lai
authors.affiliation: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Fang
authors.affiliation: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.|Department of Urology, Meizhou People's Hospital, Guangdong, China.
authors.forename: Hui-Ming
authors.initials: HM
authors.lastname: Jiang
authors.affiliation: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Lu
authors.affiliation: Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Fang-Jian
authors.initials: FJ
authors.lastname: Zhou
authors.affiliation: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Xie
authors.affiliation: Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Jun-Hang
authors.initials: JH
authors.lastname: Luo
authors.affiliation: Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000652:urine; D014408:Biomarkers, Tumor / Q000652:urine*; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000473:pathology / Q000652:urine*; D015331:Cohort Studies; D055088:Early Detection of Cancer / Q000379:methods*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000652:urine; D056921:Nuclear Receptor Coactivator 3 / Q000032:analysis / Q000652:urine*; D010448:Peptide Initiation Factors / Q000032:analysis / Q000652:urine*; D011237:Predictive Value of Tests; D016601:RNA-Binding Proteins / Q000032:analysis / Q000652:urine*; D012680:Sensitivity and Specificity; D016482:Urinalysis / Q000379:methods / Q000592:standards; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000652:urine*; D000097574:Eukaryotic Translation Initiation Factor 5A
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; D056921:Nuclear Receptor Coactivator 3; D010448:Peptide Initiation Factors; D016601:RNA-Binding Proteins; D000097574:Eukaryotic Translation Initiation Factor 5A; C100379:nuclear matrix protein 22; C538866:NCOA3 protein, human
keywords: AIB1; EIF5A2; bladder cancer; diagnostic model; urine biomarkers